Hospice Doesn't Offset Intensive End-of-Life Ovarian Cancer Care

This article originally appeared here.
Share this content:
Hospice Doesn't Offset Intensive End-of-Life Ovarian Cancer Care
Hospice Doesn't Offset Intensive End-of-Life Ovarian Cancer Care

(HealthDay News) -- Increasing use of hospice in the final days of ovarian cancer does not offset intensive end-of-life care in older women, according to a study published online Oct. 6 in the Journal of Clinical Oncology.

Alexi A. Wright, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues examined changes in medical care during the last month of life over time for 6,956 individuals (aged ≥66 years) enrolled in fee-for-service Medicare. Patients were diagnosed with epithelial ovarian cancer between 1997 and 2007, and died as a result of ovarian cancer by December 2007.

The researchers found that between 1997 and 2007, hospice use increased significantly, and terminal hospitalizations decreased (both P < 0.001). There was, however, a simultaneous, statistically significant increase in intensive care unit admissions, hospitalizations, repeated emergency department visits, and health care transitions (all P ≤ 0.01). Over time the proportion of patients referred to hospice from inpatient settings rose (P = 0.001). Compared to outpatients, inpatients referred to hospice were more likely to enroll in hospice within three days of death (adjusted odds ratio, 1.36).

"Use of hospital-based services increased over time, and patients underwent more transitions among health care settings near death, suggesting that the increasing use of hospice did not offset intensive end-of-life care," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths